Skip to the stories
Wednesday, 18 November 2026
Saved

Next edition

18:39

Headlines

Top Stories

Semaglutide repairs damaged blood vessels in chronic kidney disease patients

Researchers found that semaglutide dampens inflammation and restores blood vessel function in kidneys, offering a potential path to reverse chronic kidney disease.

FTMQ Science, written by our newsroom1 view

Share
Picture: Science News

Semaglutide, the primary active ingredient in the diabetes and weight loss medication Ozempic, improves kidney function by dampening inflammation and repairing blood vessels, Science News reported. The research findings were published on October 1 in the journal Nature Medicine. The drug acts upon the organ's vascular network, which serves as the body's primary waste filtration system. [1]

Glucagon-like peptide-1, or GLP-1, is a peptide hormone composed of 30 or 31 amino acids that is secreted by intestinal L-cells and brainstem neurons following food intake. Semaglutide mimics this natural hormone to regulate appetite and enhance glycemic control. Ozempic is administered through a once-weekly subcutaneous injection using a prefilled pen in dosages ranging from 0.25 mg to 2 mg. [4][5][6]

Safety monitors have tracked several adverse events associated with the class of medications. The Food and Drug Administration requires a warning regarding non-arteritic anterior ischemic optic neuropathy, or NAION, for Ozempic and other GLP-1 drugs, according to Consumer Notice. As FTMQ Science reported earlier, researchers linked these medications to a slightly increased risk of permanent vision loss, as well as higher rates of scalp inflammation and nail detachment. [2][6][7]

The discovery illustrates how semaglutide can actively restore biological structures damaged by chronic renal illness. The findings expand the potential therapeutic applications of GLP-1 receptor agonists beyond diabetes management and weight control to direct organ repair. [1]

Share

In short

  • Semaglutide was found to repair kidney blood vessels and reduce local inflammation.
  • The research findings were published in Nature Medicine on October 1.
  • Glucagon-like peptide-1 is a metabolic hormone produced by intestinal L-cells and brainstem neurons.
  • The FDA requires a warning label for NAION on Ozempic and other GLP-1 medications.

Sources

Every paragraph above points to the numbered items it rests on. Read the originals here.

  1. [1]Drugs like Ozempic may help reverse chronic kidney diseaseScience News, 8d ago (the report this story comes from)
  2. [2]FDA Requires NAION Warning for Ozempic, Other GLP-1 DrugsConsumer Notice, 8d ago

Background

  1. [3]List of antiviral drugs on Wikipedia
  2. [4]Glucagon-like peptide-1 on Wikipedia
  3. [5]Ozempic on Grokipedia
  4. [6]Popular GLP-1 medications linked to rare risk of sudden vision loss FTMQ Science, 34d ago
  5. [7]GLP1 medications linked to increased risk of nail detachment and scalp inflammation FTMQ Science, 36d ago

Our newsroom writes these reports with the help of software, from the 7 sources listed and nothing else, and checks them against those sources. Facts can still be wrong or move on; the originals are the record. Spotted a mistake? Write to daniel@monsterkong.com.

Earlier reports of ours on the same people and subjects.

More in Top Stories

Get the day in one email

Reports like this one, the top news of the last 24 hours, every morning. Free, one email a day; readers can comment under every report.

By signing up you agree to our terms and privacy policy. Unsubscribe any time.

Comments

Loading

Join the conversation

Comments are open to readers of our daily email: the top news of the last 24 hours, every morning, free. Sign up and the comment box opens.

Already on the list? Enter the same address and we will send a sign-in link.

By signing up you agree to our terms and privacy policy. Unsubscribe any time.